Collectively, our results suggest that CAF-derived CXCL14 targets CCR7 in bladder cancer cells, enhancing ERCC4 transcription through JAK2/STAT3 activation and subsequently binding to the ERCC4 promoter region. Here, JAK2 is linked to urinary bladder carcinoma.